OncoMatch

OncoMatch/Clinical Trials/NCT06016738

OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer

Is NCT06016738 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments for breast cancer.

Phase 3RecruitingOlema Pharmaceuticals, Inc.NCT06016738Data as of May 2026

Treatment: Palazestrant · Fulvestrant · Anastrozole · Letrozole · ExemestaneThis phase 3 clinical trial compares the safety and efficacy of palazestrant (OP-1250) to the standard-of-care options of fulvestrant or an aromatase inhibitor in women and men with breast cancer whose disease has advanced on one endocrine therapy in combination with a CDK4/6 inhibitor.

Check if I qualify

Extracted eligibility criteria

Cancer type

Breast Carcinoma

Biomarker criteria

Required: HER2 (ERBB2) negative

Required: ESR1 positive

Disease stage

Metastatic disease required

locally advanced or metastatic breast cancer that is not amenable to curative therapy. Evaluable disease (measurable disease or bone-only disease)

Performance status

ECOG 0–1(Restricted strenuous activity)

Prior therapy

Must have received: CDK4/6 inhibitor — in combination with endocrine therapy in the advanced setting

Previously received a CDK4/6 inhibitor in combination with an endocrine therapy in the advanced setting

Cannot have received: chemotherapy

Exception: in the advanced/metastatic setting

Previously received chemotherapy in the advanced/metastatic setting

Cannot have received: estrogen receptor-directed therapy (elacestrant)

Previously received treatment with elacestrant or an investigational estrogen receptor-directed therapy

Lab requirements

Blood counts

adequate hematologic function

Kidney function

adequate renal function

Liver function

adequate hepatic function

Adequate hematologic, hepatic, and renal functions

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

  • Clinical Trial Site · Tucson, Arizona
  • Clinical Trial Site · Fountain Valley, California
  • Clinical Trial Site · Glendale, California
  • Clinical Trial Site · La Jolla, California
  • Clinical Trial Site · Los Alamitos, California

Showing up to 5 US sites. See all sites on ClinicalTrials.gov →

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify